Cell cycle and molecular targets: CDK inhibition;Le cycle cellulaire et ses cibles: Inhibition des CDK

Bulletin du Cancer

Volumn 99, Issue 2, 2012, Pages 163-171

  Carassou, Philippe ^a   Meijer, Laurent ^b   Le Moulec, Sylvestre ^c   Aoun, Jean ^a   Bengrine Lefev̀re, Leila ^d  

^a Service de Médecine Interne   (France)

^b STATION BIOLOGIQUE   (France)

^c University of Paris Descartes   (France)

^d HÔPITAL SAINT ANTOINE   (France)

Author keywords

Antitumor activity; Cell cycle; Cyclin dependent kinases; Indirubin; Meriolin; Roscovitine

Indexed keywords

CYCLIN DEPENDENT KINASE;

APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; CELL PROLIFERATION; ENZYME INHIBITION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW;

EID: 84856832908     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1383     Document Type: Article

References (46)

1. Lévy A, Albiges-Sauvin L, Massard C, Soria JC, Deutsch E. Cycle cellulaire, mitose et applications thérapeutiques. Bull Cancer 2011 [Epub ahead of print].
2. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298 : 1912-34. (Pubitemid 35425239)
3. Obligado SH, Ibraghimov-Beskrovnaya O, Zuk A, Meijer L, Nelson PJ. CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases. Kidney Int 2008; 73 : 684-90. (Pubitemid 351323251)
4. Kockeritz L, Doble B, Patel S, Woodgett JR. Glycogen synthase kinase-3 - an overview of an over-achieving protein kinase. Curr Drug Targets 2006; 7 : 1377-88. (Pubitemid 44718298)
5. Schwob E. Nobel prize in medicine 2001: the universal key to cell division. Bull Cancer 2001; 88 : 937. (Pubitemid 33081843)
6. Morgan D. The Cell Cycle. Sunderland :New Science Press, 2007, 297.
7. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005; 30 : 630-41. (Pubitemid 41540083)
8. Cruz JC, Tsai LH. A Jekyll and Hyde kinase: roles for Cdk5 in brain development and disease. Curr Opin Neurobiol 2004; 14 : 390-4. (Pubitemid 38759871)
9. Meijer L. Le cycle cellulaire et sa régulation. Bull Cancer 2006; 93 : 41-53.
10. Keyomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002; 347 : 1566-75. (Pubitemid 35315837)
11. Wingate H, Puskas A, Duong M, et al. Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression. Cell Cycle 2009; 8 : 1062-8.
12. Aggarwal BB, Ichikawa H. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle 2005; 4 : 1201-15. (Pubitemid 41365390)
13. Nguyen HH, Aronchik I, Brar GA, Nguyen DH, Bjeldanes LF, Firestone GL. The dietary phytochemical indole-3-carbinol is a natural elastase enzymatic inhibitor that disrupts cyclin E protein processing. Proc Natl Acad Sci U S A 2008; 105 : 19750-5.
14. Kaldis P, Russo AA, Chou HS, Pavletich NP, Solomon MJ. Human and yeast cdk-activating kinases (caks) display distinct substrate specificities. Mol Biol Cell 1998; 9 : 2545-60. (Pubitemid 28425893)
15. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 2003; 13 : 65- 70.
16. Bloom J, Pagano M. Deregulated degradation of the cdk p27 and malignant transformation. Semin Cancer Biol 2003; 13 : 41-7. (Pubitemid 36269179)
17. Knockaert M, Greengard P, Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 2002; 23 : 417- 25.
18. Cohen P. Protein kinases - the major drug targets of the twentyfirst century? Nat Rev Drug Discov 2002; 1 : 309-15.
19. Noble ME, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science 2004; 303 : 1800-5.
20. Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclindependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004; 3 : 1427- 38.
21. Siemeister G, Luecking U, Wagner C, Detjen K, Mc Coy C, Bosslet K. Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709. Biomed Pharmacother 2006; 60 : 269-72. (Pubitemid 44223936)
22. Berthet C, Aleem E, Coppola V, Tessarollo L, Kaldis P, Berthet C. Cdk2 knockout mice are viable. Curr Biol 2003; 13 : 1775-85. (Pubitemid 37274109)
23. Santamaría D, Barrière C, Cerqueira A, et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 2007; 448 : 811-5. (Pubitemid 47266342)
24. Mettus RV, Rane SG. Characterization of the abnormal pancreatic development, reduced growth and infertility in CDK4 mutant mice. Oncogene 2003; 22 : 8413-21. (Pubitemid 37523893)
25. Davis ST, Benson BG, Bramson HN, et al. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science 2001; 291 : 134-7. (Pubitemid 32056682)
26. Price PM, Safirstein RL, Megyesi J. Protection of renal cells from cisplatin toxicity by cell cycle inhibitors. Am J Physiol Renal Physiol 2004; 286 : 378-84.
27. Meijer L, Bettayeb K, Galons H, Roscovitine H. CYC202, Seliciclib. In : Yue E, Smith PJ, editors. Inhibitors of cyclin-dependent kinases as anti-tumor agents. Boca Raton : CRC Press, 2007, p. 187-226.
28. Rebhun LI, White D, Sander G, Ivy N. Cleavage inhibition in marine eggs by puromycin and 6-dimethylaminopurine. Exp Cell Res 1973; 77 : 312-8.
29. Bach S, Knockaert M, Lozach O, et al. Roscovitine targets: protein kinases and pyridoxal kinase. J Biol Chem 2005; 280 : 31208-19. (Pubitemid 41291858)
30. Aleem E, Kiyokawa H, Kaldis P. CDC2-cyclin E complexes regulate the G1/S phase transition. Nat Cell Biol 2005; 7 : 831-6. (Pubitemid 41079056)
31. Zhang GJ, Safran M, Wei W, et al. Bioluminescent imaging of CDK2 inhibition in vivo. Nat Med 2004; 10 : 643-8. (Pubitemid 38796857)
32. Ribas J, Boix J, Meijer L. (R)-Roscovitine (CYC202 Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to Nutlin-3 induced apoptosis. Exp Cell Res 2006; 312 : 2394-400. (Pubitemid 43959856)
33. Yang-Yen HF. Mcl-1: a highly regulated cell death and survival controller. J Biomed Sci 2006; 13 : 201-4.
34. Mandelin II AM, Pope RM. Myeloid cell leukemia-1 as a therapeutic target. Expert Opin Ther Targets 2007; 11 : 363-73. (Pubitemid 46290959)
35. Inoue S, Walewska R, Dyer MJ, Cohen GM. Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells. Leukemia 2008; 22 : 819-25. (Pubitemid 351552631)
36. Meijer L. La pourpre de Méditerranée, une source inattendue d'inhibiteurs de GSK-3/Tyrian purple indirubins: a source of GSK-3 inhibitors. Med Sci (Paris) 2004; 20 : 516-8. (Pubitemid 38620591)
37. Hoessel R, Leclerc S, Endicott JA, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclindependent kinases. Nat Cell Biol 1999; 1 : 60-7. (Pubitemid 129495012)
38. Davies TG, Tunnah P, Meijer L, et al. Inhibitor binding to active and inactive CDK2. The crystal structure of a CDK2-cyclin A/indirubin-5-sulphonate. Structure 2001; 9 : 389-97. (Pubitemid 32497266)
39. Meijer L, Skaltsounis AL, Magiatis P, et al. GSK-3 selective inhibitors derived from Tyrian purple indirubins. Chem Biol 2003; 10 : 1255-66. (Pubitemid 38050973)
40. Fischer PM. CDK versus GSK-3 inhibition: a purple haze no longer? Chem Biol 2003; 10 : 1144-6. (Pubitemid 38042717)
41. Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3 specific inhibitor. Nat Med 2004; 10 : 55-63. (Pubitemid 38524699)
42. Ribas J, Yuste VJ, Garrofé-Ochoa X, Meijer L, Esquerda JE, Boix J. 7-Bromoindirubin-3′-oxime uncovers a serine protease-mediated paradigm of necrotic cell death. Biochem Pharmacol 2008; 76 : 39- 52.
43. Gompel M, Leost M, Bal de Kier Joffe E, et al. Meridianins, a new family of protein kinase inhibitors isolated from the Ascidian Aplidium meridianum. Bioorg Med Chem 2004; 14 : 1703-7. (Pubitemid 38340670)
44. Bettayeb K, Tirado OM, Marionneau-Lambert S, et al. Meriolins, a new class of cell death-inducing kinase inhibitors with inhibitors with enhanced selectivity for cyclin-dependent kinases. Cancer Res 2007; 67 : 8325-34. (Pubitemid 47395171)
45. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001; 1 : 222-31. (Pubitemid 33741897)
46. Kelland LR. Cyclin-dependent kinase inhibitors and combination therapy: experimental and clinical status. In : Yue E, Smith PJ, editors. Inhibitors of cyclin-dependent kinases as anti-tumor agents. Boca Raton : CRC Press, 2007, p. 371-88.